Commonwealth Equity Services’s Protalix BioTherapeutics PLX Stock Holding History

Commonwealth Equity Services’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.3K	Hold	19,461	–	–	﹤0.01%	4316
2026 Q1	$42.2K	Sell	19,461 -152,311	-89%	-$378K	﹤0.01%	4215
2025 Q4	$309K	Hold	171,772	–	–	﹤0.01%	3628
2025 Q3	$381K	Sell	171,772 -25,025	-13%	-$40.8K	﹤0.01%	3414
2025 Q2	$291K	Buy	196,797 +146,772	+293%	+$300K	﹤0.01%	3609
2025 Q1	$128K	Buy	50,025 +25	+0.1%	+$60	﹤0.01%	3949
2024 Q4	$94K	Hold	50,000	–	–	﹤0.01%	3918
2024 Q3	$51K	Sell	50,000 -100	-0.2%	-$105	﹤0.01%	3935
2024 Q2	$59K	Hold	50,100	–	–	﹤0.01%	3876
2024 Q1	$63K	Hold	50,100	–	–	﹤0.01%	3862
2023 Q4	$89K	Hold	50,100	–	–	﹤0.01%	3689
2023 Q3	$83K	Sell	50,100 -100	-0.2%	-$179	﹤0.01%	3595
2023 Q2	$100K	Buy	50,200 +100	+0.2%	+$238	﹤0.01%	3571
2023 Q1	$105K	Hold	50,100	–	–	﹤0.01%	3489
2022 Q4	$68K	Buy	+50,100	New	+$55K	﹤0.01%	3474
2022 Q1	–	Sell	-40,290	Closed	-$33K	–	3781
2021 Q4	$33K	Buy	+40,290	New	+$42.2K	﹤0.01%	3571
2017 Q2	–	Sell	-3,775	Closed	-$51K	–	2546
2017 Q1	$51K	Buy	+3,775	New	+$33.9K	﹤0.01%	2325

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Commonwealth Equity Services's PLX Position: Q2 2026 in Review

Commonwealth Equity Services held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 19,461 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4316.

Commonwealth Equity Services first reported a position in PLX in Q1 2017 and has held it in 17 quarters since. The position peaked at $381K in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Commonwealth Equity Services held 19,461 shares of Protalix BioTherapeutics worth $45.3K as of Q2 2026.
Commonwealth Equity Services left its Protalix BioTherapeutics share count unchanged in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4316 holding.
Commonwealth Equity Services first reported a position in Protalix BioTherapeutics in Q1 2017 and has held it in 17 quarters since.
Commonwealth Equity Services's Protalix BioTherapeutics position peaked at $381K in Q3 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.